FMP
Talaris Therapeutics, Inc.
TALS
NASDAQ
Inactive Equity
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
2.72 USD
-0.02 (-0.735%)
About
ceo
Ms. Mary Kay Fenton
sector
Healthcare
industry
Biotechnology
website
https://talaristx.com
exchange
NASDAQ
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immu...
CIK
0001827506
ISIN
US89157D1054
CUSIP
87410C104
Address
570 South Preston Street
Phone
502 398 9250
Country
US
Employee
84
IPO Date
May 7, 2021
Summary
CIK
0001827506
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
87410C104
ISIN
US89157D1054
Country
US
Price
2.72
Beta
2.18
Volume Avg.
142.92k
Market Cap
116.44M
Shares
-
52-Week
0.89-3.29
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.56
P/B
-
Website
https://talaristx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TALS News
It looks like there's no news available.
